Chronic Lymphocytic Leukemia
Featured Article
“This study shows that the adverse event burden associated with current treatments for CLL is substantial,” researchers wrote, “and the management of adverse events occurring during treatments may have a significant impact on overall healthcare costs.”
“New treatments that delay disease progression in patients with hematologic cancer could have a significant impact on the economic burden of hematologic malignancies,” researchers wrote.
By preemptively looking for patients with chronic lymphocytic leukemia (CLL) who are most likely to not respond to therapy with Bruton's tyrosine kinase (BTK) inhibitors in the long-term, or who will…